netFormulary Pan Mersey Area Prescribing Committee NHS
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Notes:

Review date: March 2020


Non-formulary drugs - any drug or formulation not listed in the formulary is deemed to be non-formulary.

Paediatrics - all drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

Chapter Links...
 Details...
02.09  Expand sub section  Antiplatelet drugs
Aspirin tablets (antiplatelet)
View adult BNF View SPC online View childrens BNF
Formulary
Green

75mg
 
Amber Initiated paediatrics

Unlicensed in children

 
Link  UKMI Q&A: Is there evidence to support the use of EC aspirin to reduce GI side effects in cardiovascular patients? (2017)
   
Cangrelor
View adult BNF View SPC online View childrens BNF
Formulary
Red
50 mg powder for concentrate for solution for injection / infusion 
Link  NICE TA351: Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)
   
Clopidogrel tablets
View adult BNF View SPC online
Formulary
Green

75mg
 
 
Amber Initiated paediatrics

Paediatrics: no BNFc entry - seek specialist advice. Dosage information from initiating centre.

 
Link  NICE TA80: Acute coronary syndromes - clopidogrel
   
Dipyridamole MR capsules
View adult BNF View SPC online
Formulary
Green
200mg

Paediatrics: no BNFc entry - seek specialist advice 
   
Dipyridamole oral suspension
View adult BNF View SPC online View childrens BNF
Formulary
Green

50mg/5ml, 200mg/5ml

Amber Initiated paediatrics

 
   
Dipyridamole tablets
View adult BNF View SPC online View childrens BNF
Formulary
Amber Initiated

25mg, 100mg

For paediatrics

 
   
Prasugrel tablets
View adult BNF View SPC online
Formulary
Amber Initiated

5mg, 10mg

Paediatrics: no BNFc entry - seek specialist advice

 
Link  NICE TA317: Acute coronary syndrome - prasugrel
   
Ticagrelor
View adult BNF View SPC online
Formulary
Amber Initiated

Tablets 90mg, 60mg

Orodispersible tablets 90mg

Maximum treatment duration of 1 year at 90mg bd; extended treatment with 60mg bd up to a maximum of 3 years.     

 

Paediatrics: no BNFc entry - seek specialist advice

 
Link  TICAGRELOR tablets (Brilique®) Pan Mersey Area Prescribing Committee Prescribing Policy Statement
Link  NICE TA236: Acute coronary syndromes - ticagrelor
Link  NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
   
Abciximab
View adult BNF View SPC online
Formulary
Red
2mg/mL, 5mL vial

Paediatrics: no BNFc entry - seek specialist advice 
   
Eptifibatide
View adult BNF View SPC online
Formulary
Red
2mg/mL 10mL vial
750micrograms/mL 100mL vial

Paediatrics: no BNFc entry - seek specialist advice 
   
Tirofiban
View adult BNF View SPC online
Formulary
Red
Concentrate for intravenous infusion, 250micrograms/mL. For dilution before use, 50mL (12.5mg) vial
Intravenous infusion, 50 micrograms/mL, 250mL bag

Paediatrics: no BNFc entry - seek specialist advice 
   
Aspirin suppositories
View adult BNF View childrens BNF
Unlicensed Drug Unlicensed
Green

Unlicensed special 

Amber Initiated paediatrics

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Medicines considered suitable for non-specialist prescribing in primary or secondary care.  

Amber Recommended

Amber Recommended  

Amber Initiated

Amber Initiated. Requires specialist initiation of prescribing. Prescribing to be continued by the specialist until stabilisation of the dose and the patient’s condition is achieved and the patient has been reviewed. Amber Initiated medicines must meet criteria: (1) Requires specialist assessment to enable patient selection (2) Medicine is suitable for on-going prescribing in Primary Care (3) Requires short to medium term specialist prescribing and monitoring of efficacy or toxicity until the patient’s dose and condition is stable   

Amber Retained

Amber Patient Retained. Requires specialist initiation of prescribing. Prescribing to be continued by specialist until stabilisation of the dose and the patient’s condition is achieved and the patient had been reviewed. Patient remains under the care of specialist (ie not discharged) as occasional specialist input may be required. Amber Patient Retained medicines must meet criteria: (1)Requires specialist assessment to enable patient selection (2)Medicine is suitable for on-going prescribing in Primary Care (3) Requires short to medium term specialist prescribing and monitoring of efficacy or toxicity until the patient’s dose and condition is stable (4) May require occasional specialist input indefinitely and therefore the patient should not be discharged from specialist care   

Amber

Medicines recommended or initiated by specialists in primary or secondary care. Non-specialist prescribing in primary care may follow according the RAG criteria. In process of being superceded by Amber Recommended, Amber Initiated and Amber Patient Retained.  

Purple

Shared Care. Medicines are considered suitable for Primary Care prescribing and/or management, following specialist initiation of therapy, with on-going communication between the Primary Care prescriber and specialist, within the framework of a Shared Care Agreement. Medicines designated as requiring Shared Care require on-going input from both Specialist and Primary Care clinicians and patients should not be discharged from Specialist care. Where prescribing and monitoring are required under shared care, it is implicit that the responsibility for both of these tasks rests with the prescriber. A Shared Care Agreement will always be available for Shared Care medicines and this document will include a Shared Care Agreement pro-forma which will be completed by all involved clinicians. This pro-forma will record agreement to take on defined aspects of care e.g. monitoring and/or on-going prescribing for the individual patients. A policy detailing clinician responsibilities in Shared Care Agreements must be referred to in all cases of Shared Care. All drugs to be included in this category must meet Shared Care criteria 1 to 3: SC1 Requires specialist assessment to enable patient selection and also initiation, stabilisation and review of treatment and the patient`s condition. SC2 Prescribing and/or management of the drug in Primary Care with specialist support and input, within the framework of the Shared Care Agreement is safe and convenient and that there is an appropriate mechanism for individual patient access in Primary Care. SC3 Requires specific long-term monitoring (blood test or other measurement) for adverse effects and / or efficacy of the drug to be completed in Primary Care, and requires on-going specialist support for the dose changes or management of adverse effects. Monitoring is required on a regular basis (typically four times a year). Implicit in any shared care agreement is the understanding that participation is at the discretion of the Primary Care prescriber subject to their clinical confidence.   

Red

Primary care prescribing of these medicines is NOT recommended. These treatments should be initiated by specialists only; ongoing prescribing is retained within secondary care.   

Black

Not recommended for use. Deviation from the policy may be considered on an individual basis where exceptional circumstances exist.   

Grey

Not recommended for use at this time. Deviation from the policy may be considered on an individual basis where exceptional circumstances exist. Further guidance will be issued when more information or evidence is made available.  

netFormulary